To investigate this hypothesis, the expression profile of galectin-3 was assessed in a panel of PD-L1-positive (tumor proportion score > 50%) non-oncogene-addicted treatment-naive metastatic NSCLCs treated with pembrolizumab. The gene discussed is CD274; the disease is neoplasm.